Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to investigate the effects of hyperic oxygen treatment on the immune response in patients with necrotizing soft tissue infections


Clinical Trial Description

Necrotizing soft tissue infections (NSTI) is a complex, multi-factorial disease and the bacteria show a diverse microbial etiology. The exentisive inflammatory response caused by these bacteria is thought to be a main course of death. In Denmark, most NSTI patients are treated with hyperic oxygen therapy (HBOT). However, the effects of HBOT have never been investigated in NSTI patients.

Location: Copenhagen University Hospital, Rigshospitalet, Denmark.

Design: Observational cohort study.

Cohort: NSTI patients in Denmark treated with HBOT.

Biomarkers: Cytokines, acute-phase proteins, vasoactive biomarkers and other inflammatory biomarkers.

Sample size calculation: The investigators expect a mean IL-6 concentration before HBOT of 3500 pg/ml (standard deviation 1500 pg/ml) and consider a reduction of 800 pg/ml to be clinically relevant. With an alpha = 0.05 and a power of 80%, 112 patients will be required.

Data: The Danish Data Protection Agency has approved the processing of personal data for the NSTI patients (J. no. 30-0900).

Ethics: The trial will adhere to the Helsinki Declaration and the Danish law. The National Ethics Committee and the Regional Scientific Ethics Committee of Copenhagen have approved the study (CVK-1211709 and H-2-2014-071).

Analysis: Biomarker analyses will be performed once the recruitment of patients has ended. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02501382
Study type Observational
Source Rigshospitalet, Denmark
Contact
Status Completed
Phase
Start date February 2013
Completion date December 1, 2015

See also
  Status Clinical Trial Phase
Terminated NCT05157360 - HAT for the Treatment of Sepsis Associated With NASTI Phase 1/Phase 2
Recruiting NCT04801615 - Characteristics of Patients With Necrotizing Soft Tissue Infections
Withdrawn NCT02314468 - Negative Pressure Wound Therapy and Allogeneic Human Skin Grafts for Wound Bed Preparation N/A
Recruiting NCT05116956 - SKin and Soft Tissue Necrotizing INfections in the Intensive Care Unit: a Prospective Multi-national Cohort Study
Terminated NCT03403751 - Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury Phase 3
Terminated NCT05032625 - To Evaluate the Outcomes After Surgery for Necrotizing Soft Tissue Infections
Recruiting NCT05243966 - Myriad™ Augmented Soft Tissue Reconstruction Registry
Active, not recruiting NCT06126263 - Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
Completed NCT02180906 - Biomarkers in Patients With Flesh-eating Bacterial Infections N/A
Completed NCT03147352 - Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study
Recruiting NCT06002607 - Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections
Completed NCT02111161 - Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Phase 2
Recruiting NCT03482245 - The Role of Circadian Clock Proteins in Innate and Adaptive Immunity N/A